126 related articles for article (PubMed ID: 17460934)
1. [Guidelines of the Israeli association of rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
Elkayam O; Balbir-Gurman A; Lidgi M; Rahav G; Weiler-Ravel D
Harefuah; 2007 Mar; 146(3):235-7, 244. PubMed ID: 17460934
[TBL] [Abstract][Full Text] [Related]
2. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
Balbir-Gurman A; Lidgi M; Elkayam O
Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
4. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
5. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
[TBL] [Abstract][Full Text] [Related]
6. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.
Keane J
Rheumatology (Oxford); 2005 Jun; 44(6):714-20. PubMed ID: 15741198
[TBL] [Abstract][Full Text] [Related]
7. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.
Chen DY; Shen GH; Chen YM; Chen HH; Hsieh CW; Lan JL
Ann Rheum Dis; 2012 Feb; 71(2):231-7. PubMed ID: 22021896
[TBL] [Abstract][Full Text] [Related]
8. Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers.
Bellofiore B; Matarese A; Balato N; Gaudiello F; Scarpa R; Atteno M; Bocchino M; Sanduzzi A
J Rheumatol Suppl; 2009 Aug; 83():76-7. PubMed ID: 19661550
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
10. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
Dinarello CA
J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
Sichletidis L; Settas L; Spyratos D; Chloros D; Patakas D
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1127-32. PubMed ID: 17044206
[TBL] [Abstract][Full Text] [Related]
12. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Gómez-Reino JJ; Carmona L; Angel Descalzo M;
Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
[TBL] [Abstract][Full Text] [Related]
14. [Tuberculosis associated with anti-TNF therapy].
Takeno M; Murakami S; Ishigatsubo Y
Nihon Rinsho; 2007 Jul; 65(7):1308-13. PubMed ID: 17642248
[TBL] [Abstract][Full Text] [Related]
15. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update.
Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E
Acta Reumatol Port; 2008; 33(1):77-85. PubMed ID: 18344925
[TBL] [Abstract][Full Text] [Related]
17. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
[TBL] [Abstract][Full Text] [Related]
18. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
19. Infections associated with tumor necrosis factor-alpha antagonists.
Rychly DJ; DiPiro JT
Pharmacotherapy; 2005 Sep; 25(9):1181-92. PubMed ID: 16164393
[TBL] [Abstract][Full Text] [Related]
20. Problems encountered during anti-tumour necrosis factor therapy.
Desai SB; Furst DE
Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
